MERCK Sharp & Dohme's Atozet/Zeteze (ezetimibe and atorvastatin) combination drug is the subject of a new Australian Public Assessment Report (AusPAR) at tga.gov.au, detailing an approved submission to extend the indication of the drug to help prevent cardiovascular disease in patients already on the maximum dose of atorvastatin.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Aug 17